Skip to content
Screener

Vertex Pharmaceuticals VRTX Europe — Product revenues, net

Other geography segments

Other
$261M-6.8%

Similar metrics at other companies

Insmed logo
INSMInternational — Product revenues, net
$46.75M+20.7%
Insmed logo
INSMUS — Product revenues, net
$378.74M+451%
Insmed logo
INSMBRINSUPRI — Product revenues, net
$309.17M
Collegium Pharmaceutical, Inc. logo
COLLAzstarys — Product revenues, net
$12.91M
Collegium Pharmaceutical, Inc. logo
COLLBelbuca — Product revenues, net
$57.67M+9.6%
Collegium Pharmaceutical, Inc. logo
COLLSegment — Product revenues, net
$199.88M+6.3%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.68B+24.1%
Enterprise value$116.81B+22.4%
P/E27.9×
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
(in millions)
United States$1,775.9$1,663.5
Outside of the United States
Europe950.0826.6
Other261.0280.1
Total revenues outside of the United States1,211.01,106.7
Total revenues$2,986.9$2,770.2

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's europe — product revenues, net?
Vertex Pharmaceuticals (VRTX) reported europe — product revenues, net of $950M in Q1 2026.
How has Vertex Pharmaceuticals's europe — product revenues, net changed year-over-year?
Vertex Pharmaceuticals's europe — product revenues, net increased by 14.9% year-over-year, from $826.6M to $950M.
What is the long-term trend for Vertex Pharmaceuticals's europe — product revenues, net?
Over 2 years (2022 to 2024), Vertex Pharmaceuticals's europe — product revenues, net has grown at a 13.0% compound annual growth rate (CAGR), from $2.71B to $3.45B.
What does europe — product revenues, net mean?
This metric represents the total net sales generated from pharmaceutical products within the European geographic segment after accounting for returns, discounts, and rebates. It reflects the company's ability to successfully commercialize its therapeutic portfolio and maintain market penetration in European healthcare markets. This figure is a critical indicator of regional demand and the effectiveness of local distribution and pricing strategies.

Ask your AI about Vertex Pharmaceuticals's europe — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude